DUBLIN, May 17, 2016 /PRNewswire/ -- Allergan plc
(NYSE:AGN) a leading global pharmaceutical company, today announced
that Brent Saunders, Allergan's CEO
and President, will be featured in a fireside chat session at the
UBS 2016 Global Healthcare Conference on Monday, May 23, 2016 at 11:00 a.m. ET at The Grand Hyatt Hotel in
New York, NY. The presentation
will be webcast live and can be accessed on Allergan's Investor
Relations web site at http://ir.allergan.com. The webcast can
also be accessed through the following URL:
https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=76_QLVVC8Y.
Logo -
http://photos.prnewswire.com/prnh/20150612/222796LOGO
An archived version will be available approximately one hour
after the live presentation ends and can be accessed at the same
locations for 180 days.
About Allergan
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a unique, global pharmaceutical company and a leader in a new
industry model – Growth Pharma. Allergan is focused on
developing, manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statement
Statements contained in
this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective of existing trends and information
as of the date of this release. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements. Actual results may differ materially
from Allergan's current expectations depending upon a number of
factors affecting Allergan's business. These factors include, among
others, the difficulty of predicting the timing or outcome of FDA
approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Quarterly Report on Form
10-Q for the quarter ended March 31,
2016 (such periodic public filings having been filed under
the "Actavis plc" name). Except as expressly required by law,
Allergan disclaims any intent or obligation to update these
forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-to-present-at-the-ubs-2016-global-healthcare-conference-300270305.html
SOURCE Allergan plc